A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) .

Trial Profile

A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) .

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Tucidinostat (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors HUYA Bioscience International
  • Most Recent Events

    • 10 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 22 Mar 2016 According to a company media release, HUYA has recently received orphan drug designation for HBI-8000 in Japan for peripheral T-cell lymphoma.
    • 25 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top